Statin treatment, phenotypic frailty and mortality among community-dwelling octogenarian men: the HBS cohort.

Show simple item record Luotola, Kari Jyväkorpi, Satu Urtamo, Annele Pitkälä, Kaisu H. Kivimäki, Mika Strandberg, Timo E. 2020-11-22T02:34:30Z 2021-12-18T03:45:29Z 2020-03
dc.identifier.citation Luotola , K , Jyväkorpi , S , Urtamo , A , Pitkälä , K H , Kivimäki , M & Strandberg , T E 2020 , ' Statin treatment, phenotypic frailty and mortality among community-dwelling octogenarian men: the HBS cohort. ' , Age and Ageing , vol. 49 , no. 2 , pp. 258-263 .
dc.identifier.other PURE: 129915308
dc.identifier.other PURE UUID: cd641878-f380-4a01-a180-b5e9b8970d34
dc.identifier.other ORCID: /0000-0001-9659-6985/work/70946033
dc.identifier.other ORCID: /0000-0001-6299-925X/work/70948476
dc.identifier.other ORCID: /0000-0002-6452-0254/work/70949157
dc.identifier.other ORCID: /0000-0001-5901-3584/work/70953673
dc.identifier.other WOS: 000518554600016
dc.description.abstract BACKGROUND: statin treatment has increased also among people aged 80 years and over, but adverse effects potentially promoting frailty and loss of resilience are frequent concerns. METHODS: in the Helsinki Businessmen Study, men born in 1919-34 (original n = 3,490) have been followed up since the 1960s. In 2011, a random subcohort of home-living survivors (n = 525) was assessed using questionnaires and clinical (including identification of phenotypic frailty) and laboratory examinations. A 7-year mortality follow-up ensued. RESULTS: we compared 259 current statin users (median age 82 years, interquartile range 80-85 years) with 266 non-users (83; 80-86 years). Statin users had significantly more multimorbidity than non-users (prevalencies 72.1% and 50.4%, respectively, P < 0.0001) and worse glucose status than non-users (prevalencies of diabetes 19.0% and 9.4%, respectively, P = 0.0008). However, there was no difference in phenotypic frailty (10.7% versus 11.2%, P = 0.27), and statin users had higher plasma prealbumin level than non-users (mean levels 257.9 and 246.3 mg/L, respectively, P = 0.034 adjusted for age, body mass index and C-reactive protein) implying better nutritional status. Despite morbidity difference, age-adjusted 7-year mortality was not different between the two groups (98 and 103 men among users and non-users of statins, respectively, hazard ratio 0.96, 95% confidence interval 0.72-1.30). CONCLUSIONS: our study suggests that male octogenarian statin users preserved resilience and survival despite multimorbidity, and this may be associated with better nutritional status among statin users. fi
dc.format.extent 6
dc.language.iso eng
dc.relation.ispartof Age and Ageing
dc.rights unspecified
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject 3121 General medicine, internal medicine and other clinical medicine
dc.subject Cholesterol
dc.subject Metabolic
dc.subject nutrition
dc.subject PREALBUMIN
dc.subject Older people
dc.subject cholesterol
dc.subject cardiovascular disease
dc.subject metabolic
dc.subject nutrition
dc.subject prealbumin
dc.subject older people
dc.subject OLDER-ADULTS
dc.title Statin treatment, phenotypic frailty and mortality among community-dwelling octogenarian men: the HBS cohort. en
dc.type Article
dc.contributor.organization HUS Heart and Lung Center
dc.contributor.organization Department of Medicine
dc.contributor.organization Clinicum
dc.contributor.organization Department of General Practice and Primary Health Care
dc.contributor.organization HUS Helsinki and Uusimaa Hospital District
dc.contributor.organization HUS Internal Medicine and Rehabilitation
dc.contributor.organization Teachers' Academy
dc.description.reviewstatus Peer reviewed
dc.relation.issn 0002-0729
dc.rights.accesslevel openAccess
dc.type.version acceptedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
Statin_Treatment.pdf 235.5Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record